The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

Rambam Health Care Campus

Overview

A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

Study Type

OBSERVATIONAL

Conditions

Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * aggressive non-Hodgkin lymphoma b cells * age 18-70 * bilirubin less then 2 * creatinine less then 2 * Pet/CT performed post 2 cycles Exclusion Criteria: * no PET/CT post 2 cycles performed * bilirubin \>2 * creatinine more then 2 * HIV positivity

Locations (1)

RAMBAM health care Campus

Haifa, Israel

Outcomes

Primary Outcomes

progression free survival

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.